Annual Results Results Snapshot
Figures in Cr
Standalone Annual Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
Annual Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 6.85% vs 3.82% in Mar 2024
Standalone Net Profit
YoY Growth in year ended Mar 2025 is 23.40% vs 5.57% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 21.95% vs 9.05% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 66.67% vs -27.03% in Mar 2024
Operating Profit Margin (Excl OI)
YoY Growth in year ended Mar 2025 has improved from Mar 2024
Compare Annual Results Of Jenburkt Pharma With
Figures in Cr
Standalone Annual Results
Change(INR)
Change(%)
Net Sales
151.69
151.46
0.23
0.15%
Other Operating Income
0.00
0.00
0.00
Total Operating income
151.69
151.46
0.23
0.15%
Raw Material Cost
8.51
88.83
-80.32
-90.42%
Purchase of Finished goods
21.26
0.00
21.26
(Increase) / Decrease In Stocks
-0.12
-6.08
5.96
98.03%
Employee Cost
45.54
21.57
23.97
111.13%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.01
0.00
0.01
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
36.10
30.59
5.51
18.01%
Total Expenditure (Excl Depreciation)
111.30
134.91
-23.61
-17.50%
Operating Profit (PBDIT) excl Other Income
40.39
16.55
23.84
144.05%
Other Income
6.72
6.23
0.49
7.87%
Operating Profit (PBDIT)
47.11
22.78
24.33
106.80%
Interest
0.45
3.05
-2.60
-85.25%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
46.66
19.73
26.93
136.49%
Depreciation
2.73
6.96
-4.23
-60.78%
Profit Before Tax
43.93
12.77
31.16
244.01%
Tax
11.87
3.33
8.54
256.46%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
32.06
9.45
22.61
239.26%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
32.06
9.45
22.61
239.26%
Equity Capital
4.41
12.71
-8.30
-65.30%
Face Value
10.00
10.00
0.00
Reserves
167.36
0.00
167.36
Earnings per share (EPS)
72.70
7.44
65.26
877.15%
Diluted Earnings per share
72.65
7.44
65.21
876.48%
Operating Profit Margin (Excl OI)
26.63%
10.93%
0.00
15.70%
Gross Profit Margin
30.76%
13.03%
0.00
17.73%
PAT Margin
21.14%
6.24%
0.00
14.90%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 151.69 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 6.85% vs 3.82% in Mar 2024
Annual - Standalone Net Profit
Standalone Net Profit 32.06 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 23.40% vs 5.57% in Mar 2024
Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 40.39 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.95% vs 9.05% in Mar 2024
Annual - Interest
Interest 0.45 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 66.67% vs -27.03% in Mar 2024
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 26.63%
in Mar 2025Figures in %
YoY Growth in year ended Mar 2025 has improved from Mar 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
